Exl-111

Novartis to acquire allergy biotech Excellergy for up to $2 billion, gaining first-in-class ECRI technology and lead candidate Exl-111 currently in Phase 1 trials.

Novartis to acquire private biotech Excellergy for up to $2B, adding next-generation anti-IgE antibody Exl-111 targeting food allergy, chronic urticaria, and allergic asthma.